Message #148 From:
NewsBot Date: November 2, 2006 03:00:00 AM
BIPH News Biophan Announces Resignation of Ross B. Kenzie from Board of Directors
ROCHESTER, N.Y.--(BUSINESS WIRE)--Biophan Technologies, Inc. (OTCBB: BIPH;
FWB: BTN), a developer of next-generation medical technology, today
announced that effective October 31, 2006, Ross B. Kenzie, citing health
reasons, has resigned from the Biophan Board of Directors. Mr. Kenzie, a
founding Board Member since December, 2000, also served on the Audit and
Compensation Committees.
“Mr. Kenzie has been a most effective and
instrumental member of the Board,” stated
Guenter Jaensch, Chairman of the Biophan Board. “We
greatly appreciate the significant contributions he has made to the
Board during his years of service. His wisdom and support will be missed
by all at Biophan. We wish him all the best, and we are grateful that he
has offered to continue to be available for advice.”
About Biophan
Biophan is dedicated to providing technologies that offer innovative and
competitive advantages to the medical device industry. The Company
licenses its technologies which improve the MRI safety and image
compatibility of medical devices to leading device manufacturers. In
addition, the Company is helping to commercialize the MYOTECH MYO-VAD™,
a new, MRI-compatible cardiac recovery system which has significant
potential to improve the treatment of many forms of heart disease.
Biophan is traded on the OTC market under the symbol BIPH, and is also
listed on the Frankfurt Stock Exchange under the symbol BTN. For more
information on Biophan, please visit our website at www.biophan.com.
Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan's actual results could differ
materially from the outcome or circumstance expressed or implied by such
forward-looking statements as a result of a variety of factors
including, but not limited to: Biophan's ability to develop its
technologies; the approval of Biophan's patent applications; the
successful implementation of Biophan's research and development
programs; the ability of Biophan to demonstrate the effectiveness of its
technology; the acceptance by the market of Biophan's technology and
products incorporating such technology, the ability of Biophan to
effectively negotiate and enter into contracts with medical device
manufacturers for the licensing of Biophan's technology; competition;
the ability of Biophan to raise capital to fund its operating and
research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan's periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read
in conjunction with Biophan's periodic filings with the SEC, which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release, and
Biophan undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
